443 related articles for article (PubMed ID: 33293830)
21. Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN.
Zhang J; Shen K; Xiao M; Huang J; Wang J; Wang Y; Hong Z
Front Genet; 2023; 14():1198834. PubMed ID: 37396034
[No Abstract] [Full Text] [Related]
22. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
Zhang L; Dong H
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
[TBL] [Abstract][Full Text] [Related]
23. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
24. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Verma T; Papadantonakis N; Peker Barclift D; Zhang L
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
[TBL] [Abstract][Full Text] [Related]
25. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
Salit RB; Deeg HJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
[TBL] [Abstract][Full Text] [Related]
26. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
Byun JM; Song S; Koh Y; Yoon SS; Kim D
Anticancer Res; 2019 Nov; 39(11):6273-6282. PubMed ID: 31704857
[TBL] [Abstract][Full Text] [Related]
27. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
28. Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
Bartels S; Vogtmann J; Schipper E; Büsche G; Schlue J; Lehmann U; Kreipe H
Eur J Haematol; 2021 Apr; 106(4):520-528. PubMed ID: 33460496
[TBL] [Abstract][Full Text] [Related]
29. The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.
Pettersson H; Adamsson J; Johansson P; Nilsson S; Palmqvist L; Andréasson B; Asp J
Front Oncol; 2023; 13():1190305. PubMed ID: 37637067
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms].
Han X; Bai BB; Feng CC; Zhao S; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):190-196. PubMed ID: 38387920
[TBL] [Abstract][Full Text] [Related]
31. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
32. Update from the latest WHO classification of MPNs: a user's manual.
Passamonti F; Maffioli M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
[TBL] [Abstract][Full Text] [Related]
33. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
34. [Myeloproliferative neoplasms - Update on diagnosis and treatment].
Meyer SC; Drexler B; Skoda RC
Ther Umsch; 2019; 76(9):487-495. PubMed ID: 32157965
[TBL] [Abstract][Full Text] [Related]
35. [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].
He ZP; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):589-594. PubMed ID: 29665937
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
37. Mutations, inflammation and phenotype of myeloproliferative neoplasms.
Hermouet S
Front Oncol; 2023; 13():1196817. PubMed ID: 37284191
[TBL] [Abstract][Full Text] [Related]
38. Experimental Modeling of Myeloproliferative Neoplasms.
Lanikova L; Babosova O; Prchal JT
Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31618985
[TBL] [Abstract][Full Text] [Related]
39. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
[TBL] [Abstract][Full Text] [Related]
40. Mutations in myeloproliferative neoplasms - their significance and clinical use.
Schischlik F; Kralovics R
Expert Rev Hematol; 2017 Nov; 10(11):961-973. PubMed ID: 28914569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]